Caren S Goldberg, Felicia Trachtenberg, J William Gaynor, William T Mahle, Chitra Ravishankar, Steven M Schwartz, James F Cnota, Richard G Ohye, Russell Gongwer, Michael Taylor, Stephen Paridon, Peter C Frommelt, Katherine Afton, Andrew M Atz, Kristin M Burns, Jon A Detterich, Kevin D Hill, Antonio G Cabrera, Alan B Lewis, Christian Pizarro, Amee Shah, Binu Sharma, Jane W Newburger
OBJECTIVE: In the SVR trial (Single Ventricle Reconstruction), newborns with hypoplastic left heart syndrome were randomly assigned to receive a modified Blalock-Taussig-Thomas shunt (mBTTS) or a right ventricle-to-pulmonary artery shunt (RVPAS) at Norwood operation. Transplant-free survival was superior in the RVPAS group at 1 year, but no longer differed by treatment group at 6 years; both treatment groups had accumulated important morbidities. In the third follow-up of this cohort (SVRIII [Long-Term Outcomes of Children With Hypoplastic Left Heart Syndrome and the Impact of Norwood Shunt Type]), we measured longitudinal outcomes and their risk factors through 12 years of age...
October 24, 2023: Circulation